English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Constitutive activation of the FMS-related tyrosine kinase-3 (FLT3) by mutations or high expression levels is common in acute leukemias.[1][1] Aberrant FLT3 signaling is mediated via the RAS/MAPK and PI-3-Kinase/AKT pathways leading to proliferation, survival, and therapy resistance.[1][1] Infants

haematologica

The role of constitutive activation of FMS-related tyrosine kinase-3 and <i>NRas/KRas</i> mutational status in infants with <i>KMT2A</i> -rearranged acute lymphoblastic leukemia

The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A -rearranged acute lymphoblastic leukemia